Cytokinetics (CYTK) Cash & Current Investments (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Cash & Current Investments of $818.6 million for Q1 2026, down 12.79% year-over-year from $938.6 million in Q1 2025, and down 7.22% quarter-over-quarter from $882.2 million in Q4 2025.
Cytokinetics (CYTK) Cash & Current Investments (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Cash & Current Investments for 17 consecutive years, with $818.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 12.79% year-over-year to $818.6 million; the TTM figure through Mar 2026 stood at $818.6 million (down 12.79% YoY), while the FY2025 annual figure was $882.2 million, down 18.04% from the prior year.
- Cash & Current Investments eased to $818.6 million in Q1 2026 per CYTK's latest filing, from $882.2 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1.1 billion in Q4 2024 and bottomed at $539.6 million in Q3 2023.
- Historically, Cash & Current Investments has averaged $791.7 million across 5 years, with a median of $818.6 million in 2026.
- Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 37.81% — and 2024, when it jumped 87.55%.
- Cytokinetics' Cash & Current Investments stood at $784.2 million in 2022, then retreated by 21.55% to $615.2 million in 2023, then soared by 74.97% to $1.1 billion in 2024, then declined by 18.04% to $882.2 million in 2025, then decreased by 7.22% to $818.6 million in 2026.
- Business Quant data shows CYTK's Cash & Current Investments at $818.6 million in Q1 2026, $882.2 million in Q4 2025, and $962.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Bn |
| Mar 31, 2026 | 818.55 Mn |
| Dec 31, 2025 | 882.22 Mn |
| Sep 30, 2025 | 962.54 Mn |
| Jun 30, 2025 | 858.14 Mn |
| Mar 31, 2025 | 938.59 Mn |
| Dec 31, 2024 | 1.08 Bn |
| Sep 30, 2024 | 1.01 Bn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 619.34 Mn |
| Dec 31, 2023 | 615.20 Mn |
| Sep 30, 2023 | 539.61 Mn |
| Jun 30, 2023 | 566.10 Mn |
| Mar 31, 2023 | 665.56 Mn |
| Dec 31, 2022 | 784.18 Mn |
| Sep 30, 2022 | 867.66 Mn |
| Jun 30, 2022 | 586.03 Mn |
| Mar 31, 2022 | 608.97 Mn |
| Dec 31, 2021 | 471.64 Mn |
| Sep 30, 2021 | 477.64 Mn |